Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Nazzareno Cervelli, Giuliano Tocci, Claudio Ferri

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish
Pages (from-to)5-7
Number of pages3
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number1
Publication statusPublished - Mar 1 2018

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this